Back to School: How biopharma can reboot drug development. Access exclusive analysis here

VIMRxyn synthetic hypericin data

VMRX (Stamford, Conn.) announced Phase I safety results with intravenous dosing in 27

Read the full 133 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE